204637-77-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-4-tert-butoxy-2-(cyclopentylMethyl)-4-oxobutanoic acid is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure and reactivity make it a valuable building block in the development of new drugs, potentially leading to innovative treatments for a range of medical conditions.
Used in Chemical Research:
In the field of chemical research, (R)-4-tert-butoxy-2-(cyclopentylMethyl)-4-oxobutanoic acid serves as a subject of study for understanding the properties and behavior of chiral compounds. Its distinct structure allows researchers to explore the effects of chirality on chemical reactions and interactions, contributing to the broader understanding of stereochemistry and its implications in various applications.
Used in Material Science:
(R)-4-tert-butoxy-2-(cyclopentylMethyl)-4-oxobutanoic acid may be utilized in the development of new materials with specific properties, such as improved stability or reactivity. Its unique molecular structure could potentially be incorporated into the design of advanced materials for use in various industries, including electronics, automotive, and aerospace.

Upstream product

• 223433-51-0 tert-butyl (R)-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(cyclopentylmethyl)-4-oxobutanoate 
• 104-97-2 cyclopentanepropanoyl chloride 
• 140-77-2 3-cyclopentylpropionic acid 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 681261-53-0 2S-(3-tert-butoxycarbonyl-2R-cyclopentylmethyl-propionylamino)-3,3-dimethyl-butyric acid benzyl ester 
• 325795-81-1 3R-cyclopentylmethyl-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-4-oxo-butyric acid tert-butyl ester 
• 1091682-05-1 (R)-N-((S)-1-{4-[benzyloxycarbonyl-(4-methyl-benzyl)-amino]-piperidine-1-carbonyl}-2,2-dimethyl-propyl)-3-cyclopentylmethyl-succinic acid tert-butyl ester 
• 1351523-99-3 (R)-tert-butyl 3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-methoxyethoxy)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoate 
• 1229363-78-3 (R)-4-((4-(2-chlorophenyl)thiazol-2-yl)(methyl)amino)-3-(cyclopentylmethyl)-4-oxo butanoic acid 
• 1229363-89-6 (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid 
• 1351523-54-0 (R)-4-((4-(2-(6-(1H-pyrazol-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)(cyclopropyl)amino)-3-(cyclopentylmethyl)-4-oxobutanoic acid 

Relevant academic research and scientific papers

Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors

Human mitochondrial peptide deformylase (HsPDF) is responsible for removing the formyl group from N-terminal formylmethionines of newly synthesized mitochondrial proteins and plays important roles in maintaining mitochondria function. It is overexpressed

N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model

Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp3) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (ΔLLE = 0.3, ΔFsp3 = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.

Synthesis method of (R) 4 (tert-butoxy) 2 (cyclopentyl methyl) 4 oxobutyric acid

The invention belongs to the field of organic chemistry, and discloses a synthesis method of a compound (R) 4 (tert-butoxy) 2 (cyclopentyl methyl) 4 oxobutyric acid of which the formula 5 is shown in the description. According to the technical scheme, 3-cyclopentyl propionyl chloride is adopted as a raw material, through chiral prothetic group induction, an alkylation reaction and a hydrolysis reaction, the compound of which the formula 5 is shown in the description is prepared. According to the synthesis method of the compound (R) 4 (tert-butoxy) 2 (cyclopentyl methyl) 4 oxobutyric acid, by adjusting the temperatures in chiral prothetic group induction, the alkylation reaction and the hydrolysis reaction and the catalysts used in chiral prothetic group induction, the alkylation reaction and the hydrolysis reaction, the compound of which the formula 5 is shown in the description is synthesized with high yield. The path is short, the aftertreatment is simple, the total yield through the three-step reaction can reach 65%, and the optical purity can reach 95% or above.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

INHIBITORS OF CATHEPSIN S

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.